Merck
HomeWebinarsRevolutionizing Drug Discovery: DEL and Micromapping Technology

Revolutionizing Drug Discovery: DEL and Micromapping Technology



WEBINAR

What Does it Cover?

The complexity of target identification requires robust, innovative methodologies to improve the efficiency and success rates for developing new therapeutics. However, traditional methods of drug discovery are often time-consuming, costly, and inefficient. In this webinar, learn how to overcome these hurdles by leveraging the power of DNA Encoded Libraries (DEL) and Micromapping technologies. The mapping platform enables precise identification of protein-protein interactions on cell membranes. Utilizing a photocatalyst-antibody conjugate, this breakthrough technology allows selective labeling of antibody-binding targets and their microenvironment protein neighbors. The DNA-encoded library (DEL) technology enables the screening of millions of small molecules and fragment-based compounds that specifically bind to protein targets in a single experiment. The unparalleled diversity of chemical compounds greatly expands the chemical space that can be explored, increasing the chances of identifying novel and potent potential drug candidates.

What Will You Learn?

  • Impact of DNA Encoded Libraries (DEL) on drug discovery.
  • Selective labeling of antibody binding targets on cell membranes.
  • Micromapping technology for precise protein interaction identification.

Speaker

Hugo Matos Viana

Hugo Matos Viana

Merck

Global Product Manager - Chemical Biology

Hugo Matos Viana is a life science professional with extensive technical and business expertise in Chemistry. In his current role, he is responsible for overseeing the Chemical Biology portfolio strategy at Merck KGaA, Darmstadt, Germany. Hugo holds a PhD in Organic Chemistry and is attending an Executive MBA program. 

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?